XML 84 R50.htm IDEA: XBRL DOCUMENT
v3.25.3

Commitments Under Research and Collaboration Agreements (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Mar. 31, 2025 | Mar. 31, 2022 | Jun. 30, 2025 | Mar. 31, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Dec. 31, 2024 | Dec. 31, 2023
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | $ 11,100 |  | $ 11,100 |
Clinical development milestones. |  |  |  |  |  | 14,000 |  | 14,000 |
Regulatory events |  |  |  |  |  | 80,000 |  | 80,000 |
Commercial sales |  |  |  |  |  | 150,000 |  | 150,000 |
Milestone payments commercial milestones |  |  |  |  |  | 12,000 |  | 12,000 |
Extension royalties |  | $ 225 |  |  |  |  |  | 225 |
Accrued extension royalties |  |  | $ 200 |  |  | 200 |  | 200 | $ 200
Development milestones |  |  |  |  |  | 32,500 |  | 32,500 |
Annual sales milestone payments |  |  |  |  |  | $ 50,000 |  | $ 50,000 |
Net profits from licensed product sales |  |  |  |  |  | 50.00% |  | 50.00% |
Payment of development milestones |  |  |  | $ 3,300 |  |  |  |  |
Accrued amount |  |  |  |  |  | $ 3,300 |  | $ 3,300 |
Patent costs reimbursements |  |  |  |  |  |  |  | 0 | 49
Accrued liabilities |  |  | 325 |  |  | 325 |  | $ 325 | 379
Net sales of licensed products milestone payment |  |  |  |  |  |  |  | $3,995 |
Other income |  |  |  |  |  | 200 | $ 3,556 | $ 3,556 |
Research and Development Expense [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | 70,000 |  | 70,000 |
Royalties amount |  |  | 6 |  | $ 6 | 12 | 12 | 25 | 25
MedImmune License Agreement [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | 244,000 |  | 244,000 |
NCI License Agreement [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | 3,995 |  |  |
Royalties amount |  |  |  |  |  | 25 |  |  |
MSK License Agreement [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payment upon achieving |  |  |  |  |  | 10,500 |  | 10,500 |
Milestone payment on net sales |  |  |  |  |  | 30,000 |  | 30,000 |
Accrued royalties |  |  | 790 |  |  | 790 |  | 790 |
VAZYME License agreement [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | 200 |  | 200 |
Accrued liabilities |  |  | $ 200 |  | $ 200 | 200 | $ 200 | 200 | 200
Other Accrued Expenses and Accounts Payable [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Patent costs reimbursements |  |  |  |  |  | 273 |  | 273 | 273
Other Accrued Expenses [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Patent costs reimbursements |  |  |  |  |  | 169 |  | 169 | 169
Accounts Payable [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  | 790
Subsequent Event [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Payment of development milestones | $ 3,300 |  |  |  |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Royalties amount |  |  |  |  |  | 20 |  | 20 |
Minimum [Member] | Research and Development Expense [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Royalties amount |  |  |  |  |  |  |  | 0 | $ 20
Minimum [Member] | NCI License Agreement [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Royalties amount |  |  |  |  |  |  |  | 25 |
Maximum [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Royalties amount |  |  |  |  |  | $ 30 |  | 30 |
Maximum [Member] | Research and Development Expense [Member] |  |  |  |  |  |  |  |  |
Commitments under Research and Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |
Royalties amount |  |  |  |  |  |  |  | $ 498,000 |

X
- Definition The amount of accrued to related party amount. + References No definition available. + Details
Name: | abp_AccruedToAmount
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales milestone payments. + References No definition available. + Details
Name: | abp_AnnualSalesMilestonePayments
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represent the clinical development milestones. + References No definition available. + Details
Name: | abp_ClinicalDevelopmentMilestones
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represent the commercial sales. + References No definition available. + Details
Name: | abp_CommercialSales
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development milestones. + References No definition available. + Details
Name: | abp_DevelopmentMilestones
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents milestone payment based on net sales + References No definition available. + Details
Name: | abp_MilestonePaymentOnNetSales
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represent the milestone payment. + References No definition available. + Details
Name: | abp_MilestonePayments
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments commercial milestones. + References No definition available. + Details
Name: | abp_MilestonePaymentsCommercialMilestones
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents milestone payments upon achieving research and development and commercialization events. + References No definition available. + Details
Name: | abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Net profits from licensed product sales. + References No definition available. + Details
Name: | abp_NetProfitsFromLicensedProductSales
Namespace Prefix: | abp_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition related to the patent costs reimbursements. + References No definition available. + Details
Name: | abp_PatentCostsReimbursements
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The company is liable for extension royalties. + References No definition available. + Details
Name: | abp_PaymentForExtensionRoyalities
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of payment of development milestones. + References No definition available. + Details
Name: | abp_PaymentOfDevelopmentMilestones
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represent the regulatory events. + References No definition available. + Details
Name: | abp_RegulatoryEvents
Namespace Prefix: | abp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_AccruedLiabilitiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details
Name: | us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement. + References No definition available. + Details
Name: | us-gaap_LongTermPurchaseCommitmentMilestones
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue and income classified as other. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_OtherIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abp_MedImmuneLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abp_NCILicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abp_VAZYMELicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesAndAccountsPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ExtinguishmentOfDebtAxis=us-gaap_AccountsPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |